Fri, Sep 19, 2014, 2:39 AM EDT - U.S. Markets open in 6 hrs 51 mins


% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • fudfighter4 fudfighter4 Apr 23, 2013 11:11 AM Flag

    A point of clarification on market cap

    Don't be misled by the opinions of posters such Rehdvm and Terry on the relevance of the recent increase in Vertex's market cap to Insmed. Both of those individuals are somewhat intellectually-challenged, and regrettably unaware of their limitations.

    That $5 billion represents the market's increase in the Company's value reflecting future sales of a drug to around 50% of the Cystic Fibrosis population. Had Insmed owned that drug and received the same news, one might expect Insmed's market cap to have increased by $5 billion.

    A very rough comparison might be as follows -

    The Vertex drug is priced at around $300,000 per patient per year. Arikace is expected to be priced at around $30,000 per patient per year.

    As many CF patients will use Arikace as are expected to use the Vertex drug - imo at least 60% compared with 50% for the Vertex drug.

    The recent Vertex results were Phase II. One would expect the increase to have been net of a hefty discount - reflecting the chance of failure at Phase III, and the delay represented by the time it will take to conduct the Phase III studies.

    The mid-year Arikace results will be pivotal Phase III - and the earlier Phase II results evidence FEV-1 improvement arguably more impressive than in the recent Vertex results.

    Assuming the $5 billion increase was a fair reflection of the news, one assumes that had the results been Phase III the news would have warranted an increase in market cap of at least $8 billion.

    An 'apples for apples' increase in market cap for Insmed would be calculated as follows -

    $8 billion / $300,000 x $30,000 / 50 x 60 = $960 million, an increase of around $30 a share.

    Not much. But bear in mind that CF is only the fourth-largest Arikace opportunity. The implications of confirmation of a substantial reduction in bacterial density could deliver a market cap which reflects far greater expectations.

    Rehdvm and Terry - if you still don't understand how this works, please don't hesitate to ask questions.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
13.18-0.11(-0.83%)Sep 18 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Oracle Corporation
NYSEThu, Sep 18, 2014 4:04 PM EDT
Concur Technologies, Inc.
NasdaqGSThu, Sep 18, 2014 4:00 PM EDT
Rite Aid Corporation
NYSEThu, Sep 18, 2014 4:02 PM EDT